Presentations at ACC.24 Scientific Sessions (6-8 April 2024, Atlanta, USA and online) included latest updates from key trials of TG-targeting therapies including results with olezarsen from Balance in patients with Familial Chylomicronaemia Syndrome and BRIDGE-TIMI 73a in patients with hypertriglyceridaemia and high cardiovascular risk, as well as final data from SHASTA-2 in patients with severe hypertriglyceridaemia treated with plozasiran, and Phase 1 results with sobinsiran in mixed dyslipidaemia. There were also real world findings in patients newly prescribed icosapent ethyl, and new insights on links between hypertriglyceridaemia and multi-organ disease and all-cause mortality.
Read the reports:
- Balance trial data support olezarsen in familial chylomicronaemia syndrome
- Final SHASTA-2 trial results support efficacy and safety profile
- Real world analysis indicates MACE benefits of icosapent ethyl
- Bridge–TIMI 73a trial supports olezarsen in hypertriglyceridaemia
- Solbinsiran reduces ANGPTL3 and TG in Phase 1 study
- Hypertriglyceridaemia and multi-organ disease
- Triglycerides and all-cause mortality
Reportage by Jenny Bryan